Effects of short‐acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes
- 6 October 2021
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 24 (2) , 221-227
Abstract
Aim: To evaluate the efficacy of the short‐acting glucagon‐like peptide‐1 receptor agonist, exenatide, added to insulin therapy in type 1 diabetes on bone mineral density and bone turnover markers. Materials and Methods: In a randomized, double‐blinded, parallel‐group trial, 108 individuals with type 1 diabetes aged 18 years or older on basal‐bolus therapy with HbA1c 59‐88 mmol/mol (7.5%‐10.0%) and body mass index of more than 22.0 kg/m 2 were randomized (1:1) to preprandial subcutaneous injection of 10 μg exenatide (Byetta) before breakfast, lunch, and dinner over 26 weeks as add‐on treatment to insulin therapy. Results: Exenatide elicited a body weight reduction of 4.4 kg compared with placebo, but no between‐group differences in bone mineral density, as assessed by whole‐body, hip, lumbar, and forearm dual‐energy X‐ray absorptiometry following 26 weeks of treatment, were observed. Fasting plasma levels of C‐terminal telopeptides of type I collagen, a marker of bone resorption, and amino‐terminal propeptide of type I procollagen, a marker of bone formation, were unchanged by exenatide compared with placebo after 26 weeks. Conclusions: Despite an exenatide‐induced body weight reduction, no changes in bone metabolism were observed with exenatide added to insulin therapy in type 1 diabetes after 26 weeks.Keywords
Funding Information
- AstraZeneca Pharma Poland
This publication has 32 references indexed in Scilit:
- Glycated Hemoglobin Level and Risk of Hip Fracture in Older People with Type 2 Diabetes: A Competing Risk Analysis of Taiwan Diabetes Cohort StudyJournal of Bone and Mineral Research, 2015
- High glucose inhibits receptor activator of nuclear factor-κB ligand-induced osteoclast differentiation via downregulation of v-ATPase V0 subunit d2 and dendritic cell-specific transmembrane proteinMolecular Medicine Reports, 2014
- Biochemical markers of bone turnover in diabetes patients—a meta-analysis, and a methodological study on the effects of glucose on bone markersOsteoporosis International, 2014
- Diabetes, Collagen, and Bone QualityCurrent Osteoporosis Reports, 2014
- High serum pentosidine but not esRAGE is associated with prevalent fractures in type 1 diabetes independent of bone mineral density and glycaemic controlOsteoporosis International, 2014
- In Vivo Assessment of Bone Quality in Postmenopausal Women With Type 2 DiabetesJournal of Bone and Mineral Research, 2013
- High glucose concentrations alter the biomineralization process in human osteoblastic cellsBone, 2012
- Mortality and cause of death in hip fracture patients aged 65 or older - a population-based studyBMC Musculoskeletal Disorders, 2011
- Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetesDiabetes, Obesity and Metabolism, 2011
- Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysisOsteoporosis International, 2006